tirzepatide surpass SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Tirzepatide cardiovascular event risk assessment:
Description
Also, while it is usually fine to eat dairy, it is best to monitor individual tolerance since some people may experience unique reactions to combining dairy with their medication
Tap and distilled water are not sterile
A clear solution that turns cloudy or discolored should be discarded
These metabolic improvements were attributed to AMPK activation in the liver and adipose
They're different bets on which hormonal combination produces the best outcome and right now, only one of those bets has been tested at Phase 3 scale
